0002023557-25-000004.txt : 20250827 0002023557-25-000004.hdr.sgml : 20250827 20250827162152 ACCESSION NUMBER: 0002023557-25-000004 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20250827 DATE AS OF CHANGE: 20250827 EFFECTIVENESS DATE: 20250827 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Absco Therapeutics, Inc. CENTRAL INDEX KEY: 0002023557 ORGANIZATION NAME: EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-556003 FILM NUMBER: 251265519 BUSINESS ADDRESS: STREET 1: 127 WESTERN AVENUE CITY: ALLSTON STATE: MA ZIP: 02134 BUSINESS PHONE: 314-917-7620 MAIL ADDRESS: STREET 1: 127 WESTERN AVENUE CITY: ALLSTON STATE: MA ZIP: 02134 D 1 primary_doc.xml X0708 D LIVE 0002023557 Absco Therapeutics, Inc. 127 WESTERN AVENUE ALLSTON MA MASSACHUSETTS 02134 314-917-7620 DELAWARE None None Corporation true 2024 Stephen Linderman 127 Western Avenue Allston MA MASSACHUSETTS 02134 Executive Officer Director Avik Som 127 Western Avenue Allston MA MASSACHUSETTS 02134 Director Carlo Giovanni Traverso 127 Western Avenue Allston MA MASSACHUSETTS 02134 Director Biotechnology Decline to Disclose 06b false 2025-08-18 false true true false 0 5000000 5000000 0 false 1 0 0 0 false Absco Therapeutics, Inc. /s/ Stephen Linderman Stephen Linderman Chief Executive Officer 2025-08-27